SecBot SecBot
PRESS-RELEASE ·Filed Jul 12, 2026

EVAX

Evaxion
NEUTRAL
Impact 3/10
Horizonmonths Processed4mo ago WireGlobeNewswire
Press release · Announcement
Actionable Insight • Neutral

Preclinical data updates for early-stage programs (EVX-V1) are low-impact catalysts at a $26M market cap. The stock may see minimal short-term movement from this scientific conference presentation. Monitor for next clinical-stage milestone (e.g., Phase 1 initiation or IND filing) or partnership news for meaningful re-rating.

DirectionNeutral
Confidencemedium
Horizonmonths

How the stock moved after the report

⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60
Entry
$3.02
T+0 close · Jul 12, 2026 · via day close
Latest settled
+4.64%
T+60 · $3.16
Vs SPY
+0.64%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jul 13 $3.02entry
  2. T+1 · 4mo ago +0.33%α −0.02% · $3.03
  3. T+5 · 4mo ago +1.82%α +2.61% · $3.08
  4. T+20 · 3mo ago +0.99%α −2.19% · $3.05
  5. T+60 · 6w ago +4.64%α +0.64% · $3.16
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Evaxion presented new preclinical data at the International Herpesvirus Workshop 2026 for its CMV vaccine program EVX-V1, showing AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice. The data support the multi-component vaccine concept but is preclinical, no new clinical milestones, no regulatory action, and no financial figures were disclosed in the press release.

Key Facts

  • Data presented at International Herpesvirus Workshop 2026 in Montreal
  • New data show AI-discovered T-cell epitopes improved control of acute infection, latency, and reactivation in CMV-infected mice
  • EVX-V1 combines novel AI-discovered B-cell and T-cell antigens with AI-optimized versions of established CMV vaccine antigens
  • No licensed CMV vaccine exists currently
  • No financial data, clinical trial results, or regulatory milestones mentioned

Financial Impact

No financial figures disclosed; preclinical data only, no revenue or earnings impact

Risk Factors

  • EVX-V1 is preclinical, years away from potential approval and commercialization
  • No CMV vaccine has been approved despite decades of research, highlighting high scientific risk
  • Company has no disclosed revenue stream and requires additional capital to advance pipeline

Market Snapshot

Exchange
Nasdaq
Sector
Biological Products, (No Diagnostic Substances)
Analyst Consensus
90% bullish (10 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3325846

Track record

50 reports on EVAX

Performance horizon

7 of 11 bullish or bearish reports moved the stock their way by T+1. Best: +22.94% at T+5 after the Mar 5, 2026 report. 10 of 11 went positive at some point.

Filters
  1. Nov 12, 20264d ago 6-K Neutral 2/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  2. Nov 12, 20264d ago Press Release Neutral 1/10 Entry $2.77 to $2.74 Now $2.77 −0.00% ▼ −1.08% −0.72% vs SPY
  3. Nov 9, 20267d ago 6-K / F-1/A / PRESS-RELEASE Neutral 3/10 Entry $2.75 to $2.86 Now $2.77 +0.73% ▲ +4.00% +4.37% vs SPY
  4. Nov 6, 202610d ago 6-K Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  5. Nov 6, 202610d ago Press Release Neutral 4/10 Entry $3.00 to $2.75 Now $2.77 −7.67% ▼ −8.33% −10.70% vs SPY
  6. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  7. Nov 4, 202612d ago 6-K Neutral 3/10 Entry $2.97 to $2.76 Now $2.77 −6.73% ▼ −7.07% −2.66% vs SPY
  8. Nov 3, 202613d ago 6-K Neutral 4/10 Entry $2.96 to $2.97 Now $2.77 −6.42% ▲ +0.34% −1.31% vs SPY
  9. Oct 30, 202617d ago 6-K Neutral 2/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
  10. Oct 30, 202617d ago Press Release Neutral 3/10 Entry $2.93 to $2.92 Now $2.77 −5.46% ▼ −0.34% +0.14% vs SPY
Showing 10 of 50

US Market Status

Market Closed · Opens in 6h 38m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jul 12, 2026